Molecular Oral Pathophysiology
The high prevalence of oral (tumoral, metabolic, infectious, genetic) diseases is a societal concern per se and in their major treatment costs and pitfalls. Jaw mineralized tissues are complex, multiple, interdependent and much less studied than long bones. Our goal is to delineate presently unknown integrative biological frames in jaws and promote innovative oral biotherapies. Site-specific regulatory pathways (transcription factor, matrix peptides1) controlling mineral quality, cell fate and bone (re)modelling rates are analyzed due to original modelizations. Tooth and bone regeneration projects are based on the mimicry of the oral circuities we identify, notably in (neural-crest vs mesoderm) lineage studies and ongoing Hospital Research PHRC program on vital pulp therapy (S Simon) or orthodontics (Beatriz Castaneda).
Oral microenvironment is explored though multiscale levels, from anatomy to cell and molecular biology, to nano-minerals.
A. MicroCT mouse maxilla after molar extraction B. Enamel apatite C. Gingival cell sphere (fibronectin/vimentin/DAPI)
Experimentally studied targets in murine species are also analyzed in human cells (in vitro, in vivo cell therapy and pharmacological assays) based on our follow-up of thousands of rare genetic buccal disease cases2.
Team ongoing projects: 1. Transcriptional regulation of mineral quality is analyzed through Msx homeoprotein, steroid receptor and extracellular peptides cross-talks during matrix deposition and mineralization. Enamel defects provide unique landmarks for environmental health disturbances3 studied in a CRC network (eye, intestine, kidney). 2. Differentiation properties of neurectodermal cells which we evidenced as distinct from mesodermal cell fates, are explored in human and mouse cell clones4. New materials and cell therapy projects for dentin and bone regeneration are set up in the team mouse clinics. 3. Jaw remodeling is analyzed under extreme conditions, with the recent implementation of drugs which blocked cherubism lesion growth5. This is supported by Health Ministry “Head&Neck” Action we have set up.
Team Leader : Ariane BERDAL (DDS-PhD)
Team Members : Inserm staff is associated to University staff, linking the two dental faculties of Sorbonne Paris-Cité and the school of Medicine of Paris-Descartes University (Maxillo-facial Surgery):
Contact : 33 1 44 27 55 82 / 33 1 44 27 55 79
Administration : Shu-Chiung KOVATS
SPC Master/PhD : Emile MARIE-ROSE
- Jedeon K*, Loiodice S*, Salhi K., Le Normand M., Houari S., Chaloyard J., Berdal A., Babajko S. Androgen receptor involment in rat amelogenesis : an additional way for endocrine-disrupting chemicals to affect enamel synthesis. Endocrinology, 2016, en20161342. (*co-auteurs) .
- Yamaguti P.M., Neves FA, Hotton D, Bardet C, de La Dure-Molla M, Castro LC, Scher MD, Barbosa ME, Ditsch C, Fricain JC, de La Faille R, Figueres ML, Vargas-Poussou R, Houiller P, Chaussain C, Babajko S., Berdal* A, Acevedo* AC. Amelogenesis imperfecta in famillial hypomagnesaemia and hypercalciuria with nephrocalcinosis caused by CLDN19 gene mutations. J Med Genet., 2016. pii: jmedgenet-2016-103956. (*co-auteurs)
- Fournier B.P., Loison-Robert L.S., Ferré F.C., Owen G.R., Larjava H., Häkkinen L. Characterization of human gingival neural crest-derived stem cells in monolayer and neurosphere cultures. Eur. Cell Mater., 31 : 40-58, 2016..
- Amri N, Djolé SX, Petit S, Babajko S, Coudert AE, Castaneda B*, Simon S*, Berdal A*. Distorted patterns of dentinogenessis and eruption in Msx2 null mutants : in volvement of Sost/Sclerostin. Am J Pathol., 2016. pii: S0002-9440(16)30240-1. (*co-auteurs)
- Berès F., Isaac J., Mouton L., Rouzière S., Berdal A., Simon S., Dessombz A. Comparative physicochemical analysis of pulp stone and dentin. J. Endod., 42(3) : 432-438, 2016.
- Kadlub N., Vazquez M.P., Galmiche L., L'Herminé A.C., Dainese L., Ulinski T., Fauroux B., Pavlov I., Badoual C., Marlin S., Deckert M., Leboulanger N., Berdal A., Descroix V., Picard A., Coudert A.E. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism. J. Bone Miner. Res., 30(5) : 878-885, 2015